Clinical trial
Interleukin-2 in Treating Patients With Myelodysplastic Syndrome
NCT00002746 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00002746 |
|---|---|
| Title | Interleukin-2 in Treating Patients With Myelodysplastic Syndrome |
| Official title | A PHASE I TRIAL OF SUBCUTANEOUS, OUTPATIENT INTERLEUKIN-2 FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) |
| Lead sponsor | University of Washington, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms |
| Intervention type | Biological |
| Interventions | aldesleukin |
| Enrollment | 24 |
| Start date | Jan 1, 1996 |
| Primary completion | Apr 1, 2004 |
| Completion | Apr 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 27, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: